title: Blinatumomab: a novel agent to treat minimal residual disease in patients with acute lymphoblastic leukemia.
authors.affiliation: Cleveland Clinic Lerner College of Medicine, Department of Hematologic Oncology and Blood Disorders, The Cleveland Clinic, Cleveland, Ohio, USA.
authors.forename: Anjali S
authors.initials: AS
authors.lastname: Advani
mesh_terms: D018033:Antibodies, Bispecific / Q000008:administration & dosage* / Q000276:immunology / Q000627:therapeutic use; D018941:Antigens, CD19 / Q000276:immunology; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000276:immunology / Q000627:therapeutic use; D017209:Apoptosis; D017252:CD3 Complex / Q000276:immunology; D002986:Clinical Trials as Topic; D018572:Disease-Free Survival; D005434:Flow Cytometry; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016130:Immunophenotyping; D008213:Lymphocyte Activation; D018365:Neoplasm, Residual / Q000188:drug therapy / Q000276:immunology / Q000401:mortality; D016133:Polymerase Chain Reaction; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality; D055502:Secondary Prevention; D013601:T-Lymphocytes / Q000187:drug effects* / Q000201:enzymology
chemical_list: D018033:Antibodies, Bispecific; D018941:Antigens, CD19; D000970:Antineoplastic Agents; D017252:CD3 Complex; C510808:blinatumomab